Biotech RadarJobs updated

COMPANY

NGM Biopharmaceuticals

HQ: South San Francisco, CA source · ngmbio.com ↗ · West Coast

Clinical Phase 3

Keywords: antibody Colorectal Cancer Pancreatic Cancer Melanoma Non-small Cell Lung Cancer Gastric Cancer Esophageal Cancer Ovarian Cancer Prostate Cancer Breast Cancer Cervical Cancer Endocervical Cancer Squamous Cell Carcinoma of Head and Neck Renal Cell Carcinoma Mesothelioma Cholangiocarcinoma Geographic Atrophy Primary Sclerosing Cholangitis Bladder Urothelial Cancer Obesity Primary Biliary Cirrhosis Diabetes Mellitus CRC CRC (Colorectal Cancer) Cancer Cachexia Nonalcoholic Steatohepatitis NASH - Nonalcoholic Steatohepatitis Metastatic Castration-resistant Prostate Cancer Bladder Cancer Head Neck Squamous Cell Carcinoma Compensated Cirrhosis Colorectal Carcinoma Glioblastoma Pancreatic Ductal Adenocarcinoma SARS-CoV-2 Infection Impaired Hepatic Function NAFLD Impaired Renal Function Cachexia

Location: South San Francisco, CA · source · Oct 15, 2026

Profile checked Oct 10, 2026

26Trials (company is sponsor)

Timeline

  1. Trial start Phase 2: An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia. source ↗
  2. Trial start Phase 2/Phase 3: A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis. source ↗
  3. Trial start Phase 2: Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies source ↗
  4. Trial start Phase 1: Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors source ↗
  5. Trial start Phase 1: Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors source ↗
  6. Trial start Phase 1/Phase 2: Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies source ↗
  7. Trial start Phase 1: Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese Subjects source ↗
  8. Trial start Phase 1: Study of Aldafermin (NGM282) in Participants With Impaired Hepatic Function source ↗
  9. Trial start 1: A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by source ↗
  10. Trial start Phase 2: A Study of NGM621 in Participants With Geographic Atrophy source ↗
  11. Trial start Phase 2: Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4) source ↗
  12. Trial start Phase 1: Study of NGM395 in Adult Participants source ↗
  13. Trial start Phase 1: Study of Aldafermin (NGM282) in Participants With Impaired Renal Function source ↗
  14. Trial start Phase 1/Phase 2: Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy source ↗
  15. Trial start Phase 1: Study of NGM621 in Participants With Geographic Atrophy source ↗
  16. Trial start 2: Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage source ↗
  17. Trial start Phase 1: Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult Subjects source ↗
  18. Trial start Phase 1: Study of NGM313 in Obese Participants source ↗
  19. Trial start Phase 2: A Study of NGM282 in Patients With Primary Sclerosing Cholangitis source ↗
  20. Trial start 1: Phase 1 Study of NGM313 in Healthy Adult Participants source ↗
  21. Trial start Phase 1/Phase 2: Study of NGM282 in Subjects With Functional Constipation and Healthy Individuals source ↗
  22. Trial start Phase 2: Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH) source ↗
  23. Trial start 2: Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis source ↗
  24. Trial start 2: Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis source ↗
  25. Trial start 2: Phase 2 Study of NGM282 in Patients With Type 2 Diabetes source ↗

Showing 25 of 26 dated events.

Upcoming milestones

Estimated primary completion per ClinicalTrials.gov. Dates move.

Clinical trials (lead sponsor) 26

RecordTitlePhaseStatusStartPrimary completion
NCT07511972Study of NGM707 in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesPhase 2WithdrawnNov 14, 2023Dec 31, 2024 (estimated)
NCT07033026An Evaluation of NGM120 in a Randomized, Double-blind, Placebo-controlled Study in Participants With Colorectal Cancer Who Have Cancer Cachexia.Phase 2RecruitingJun 25, 20252027-04 (estimated)
NCT02443116Study of NGM282 in Patients With Nonalcoholic Steatohepatitis (NASH)Phase 2CompletedJul 31, 2015Dec 6, 2019 (actual)
NCT03912532Evaluation of Efficacy, Safety and Tolerability of Aldafermin in a Phase 2b, Randomized, Double-blind, Placebo-controlled, Multi-center Study In Subjects With Nonalcoholic Steatohepatitis and Stage 2/3 Fibrosis (ALPINE 2/3)2CompletedMay 16, 2019Mar 4, 2021 (actual)
NCT04465955A Study of NGM621 in Participants With Geographic AtrophyPhase 2CompletedJul 22, 2020Aug 16, 2022 (actual)
NCT02704364A Study of NGM282 in Patients With Primary Sclerosing CholangitisPhase 2Completed2016-032017-06 (actual)
NCT04068896Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination TherapyPhase 1/Phase 2CompletedOct 16, 2019Sep 21, 2023 (actual)
NCT06654726A Multi-center Evaluation of Aldafermin in a Randomized, Double-blind, Placebo-controlled Study in Subjects With Primary Sclerosing Cholangitis.Phase 2/Phase 3WithdrawnOct 21, 2024Dec 5, 2024 (actual)
NCT04210245Study of Aldafermin (NGM282) in Subjects With Compensated Cirrhosis (ALPINE 4)Phase 2CompletedMar 23, 2020Jan 4, 2023 (actual)
NCT05215574Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid TumorsPhase 1Active, not recruitingMar 31, 20222025-07 (estimated)
NCT04913337Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesPhase 1/Phase 2Unknown status (ClinicalTrials.gov)Jun 9, 20212025-02 (estimated)
NCT05311618Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid TumorsPhase 1Unknown status (ClinicalTrials.gov)May 11, 20222025-04 (estimated)
NCT04582318A Phase 1/2 Study to Assess the Safety, Tolerability and Pharmacokinetics of NGM621 in Healthy Subjects, and to Assess the Safety, PK and Efficacy in Subjects With Moderate to Severe ARDS Caused by COVID-191TerminatedNov 9, 2020Feb 18, 2021 (actual)
NCT04828265Study of Aldafermin (NGM282) in Healthy Adult Male Japanese and Non-Japanese SubjectsPhase 1CompletedApr 13, 2021Jul 6, 2021 (actual)
NCT04823702Study of Aldafermin (NGM282) in Participants With Impaired Hepatic FunctionPhase 1CompletedApr 1, 2021Nov 19, 2021 (actual)
NCT04187339Study of NGM395 in Adult ParticipantsPhase 1CompletedFeb 13, 2020Oct 20, 2020 (actual)
NCT04014777Study of NGM621 in Participants With Geographic AtrophyPhase 1CompletedJul 26, 2019May 27, 2020 (actual)
NCT04179630Study of Aldafermin (NGM282) in Participants With Impaired Renal FunctionPhase 1CompletedNov 8, 2019Dec 4, 2019 (actual)
NCT03392116Single and Multiple Ascending Dose Study of NGM120 in Healthy Adult SubjectsPhase 1CompletedJan 29, 2018Jan 14, 2019 (actual)
NCT03298464Study of NGM313 in Obese ParticipantsPhase 1CompletedSep 11, 2017Jun 19, 2018 (actual)
NCT02649062Study of NGM282 in Subjects With Functional Constipation and Healthy IndividualsPhase 1/Phase 2Completed2015-122017-01 (actual)
NCT02708576Phase 1 Study of NGM313 in Healthy Adult Participants1Completed2016-022017-04 (actual)
NCT02135536Phase 2b Study of NGM282 Extended Treatment in Patients With Primary Biliary Cirrhosis2Completed2014-052016-02 (actual)
NCT02026401Phase 2 Study of NGM282 in Patients With Primary Biliary Cirrhosis2Completed2014-022014-12 (actual)
NCT01943045Phase 2 Study of NGM282 in Patients With Type 2 Diabetes2Completed2013-092014-09 (actual)
NCT01776528Phase 1 SAD and MAD Study of NGM282 in Healthy Adult Participants1Completed2013-012013-07 (actual)
Feedback